Русский
Experience with the use of baricitinib in the treatment of atopic dermatitis in HIV-infected patients
DOI: https://dx.doi.org/10.18565/pharmateca.2022.10.26-30
E.Yu. Evdokimov, Zh.B. Ponezheva, E.V. Svechnikova, B.M. Gruzdev
1) Central Research Institute of Epidemiology, Moscow, Russia; 2) Polyclinic № 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russia; 3) Novosibirsk State Medical University, Russia; 4) Infectious Clinical Hospital № 2 of the Moscow Healthcare Department, Moscow, Russia
Background. Among HIV-infected patients, atopic dermatitis (AD) occurs more frequently by 30% than in patients without HIV infec- tion, and is characterized by severe dermatological symptoms and severe skin itch. For this reason, the treatment of AD and pruritus in HIV-infected patients remains relevant.
Objective. Evaluation of the possibility of using the baricitinib in HIV-infected patients with AD.
Methods. 6 HIV-infected patients with AD were followed-up; all patients received antiretroviral therapy (ART). There were 4 men (66.7%), 2 women (33.3%). The median age was 32.7 years (21–43). The mean duration of AD was 14.5 years (min – 7.1 years, max
– 22). SCORAD – 74.8 (min – 28, max – 89). The mean duration of HIV infection was 3.8 years (min – 0.7 years, max – 11 years), the duration of ART averaged 3.4 years (min – 0.5 years, max – 9.6). All patients were examined before prescribing baricitinib.
Results. In HIV-infected patients with AD, a pronounced clinical improvement in the general condition, a significant decrease in skin itching, and a decrease in the intensity of dermatological symptoms were noted after 12 weeks. There was no dete- rioration in the indicators of HIV infection (clinical course, decrease in the number of CD4+ lymphocytes, an increase in the viral load of HIV).
Conclusion. Baricitinib in HIV-infected patients can be used for the treatment moderate to severe AD.
Objective. Evaluation of the possibility of using the baricitinib in HIV-infected patients with AD.
Methods. 6 HIV-infected patients with AD were followed-up; all patients received antiretroviral therapy (ART). There were 4 men (66.7%), 2 women (33.3%). The median age was 32.7 years (21–43). The mean duration of AD was 14.5 years (min – 7.1 years, max
– 22). SCORAD – 74.8 (min – 28, max – 89). The mean duration of HIV infection was 3.8 years (min – 0.7 years, max – 11 years), the duration of ART averaged 3.4 years (min – 0.5 years, max – 9.6). All patients were examined before prescribing baricitinib.
Results. In HIV-infected patients with AD, a pronounced clinical improvement in the general condition, a significant decrease in skin itching, and a decrease in the intensity of dermatological symptoms were noted after 12 weeks. There was no dete- rioration in the indicators of HIV infection (clinical course, decrease in the number of CD4+ lymphocytes, an increase in the viral load of HIV).
Conclusion. Baricitinib in HIV-infected patients can be used for the treatment moderate to severe AD.
About the Autors
Corresponding author: Evgeny Yu. Evdokimov, Cand. Sci. (Med.), Researcher at the Clinical Department, Central Research Institute of Epidemiology, Moscow, Russia: evdokimovevg@yandex.ru
Similar Articles
